Supplemental Online Content

Gal R, van Velzen SGM, Hooning MJ, et al. Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer. Published online May 6, 2021. *JAMA Oncol.* doi:10.1001/jamaoncol.2021.1144

eMethods. Coronary artery calcium scoring

eTable 1. ICD-10 codes used to identify patients that experienced a cardiovascular event

eTable 2. Number of hospitalizations of cardiovascular disease and deaths by CAC score category during a median follow-up of 4.3 years

eTable 3. Number of hospitalizations for other heart diseases (I30-49, I51) during a median follow-up of 4.3 years

eTable 4. Risk of cardiovascular disease by log(CAC+1)

eTable 5. Risk of coronary artery disease by CAC score category, stratified by treatment

eTable 6. Risk of all-cause mortality by CAC score category, stratified by treatment (follow-up until 2018)

eTable 7. Number of hospitalizations of cardiovascular disease and deaths by CAC score category in patients without and with CVD hospitalization before the radiotherapy planning CT scan

eTable 8. Risk of cardiovascular disease by CAC score category in patients without known cardiovascular disease before the radiotherapy planning CT scan

eTable 9. Competing risks survival analysis of cardiovascular disease by CAC category **eFigure 1.** Cumulative incidence curves for CVD by CAC category in the presence of competing risks (Aalen-Johansen estimates and 95% intervals

This supplemental material has been provided by the authors to give readers additional information about their work.

Figure 1. Workflow of automatic CAC scoring and score computation. First, CAC is automatically identified and segmented using the deep learning calcium scoring algorithm. Second, CAC scores are computed using the Agatston scoring method.







Figure 2. Examples of CAC lesions in different coronary arteries identified by the deep learning algorithm. The position of the slices within the heart is indicated in the coronal view.




Axial view



Axial view



Axial view



Coronal view

eTable 1 ICD-10 codes used to identify patients that experienced a cardiovascular event

Diagnosis	ICD-10 codes				
Any CVD event	l00-199 except l88-l89 (lymphedema) and l83-86 (varicose veins)				
Coronary artery disease	l20-25 (e.g. myocardial infarction and angina pectoris)				
Heart failure	150				
Other heart disease	I30-49, I51 (e.g. pericarditis, endocarditis, myocarditis, cardiomyopathy, atrial fibrillation and arrhytmia)				
Cerebrovascular diseases	l60-69 (e.g. hemorrhage and cerebral infarction)				
Disease of the arteries, arterioles and capillaries	I80-82, I87, I95-97 (e.g. thrombosis and hypothension)				

		CAC score (Agatston units)								
	Total (n = 15,915)	0 (n = 11,179)	1-10 (n = 1,584)	11-100 (n = 1,825)	101-400 (n = 830)	>400 (n = 497)				
Hospital admission, n (%)										
Any cardiovascular disease	1,341 (8.4)	643 (5.8)	146 (9.2)	260 (14.3)	154 (18.6)	138 (27.8)				
Coronary artery disease	336 (2.1)	127 (1.1)	37 (2.3)	70 (3.8)	51 (6.1)	51 (10.3)				
Heart failure	185 (1.2)	84 (0.8)	15 (0.9)	34 (1.9)	27 (3.3)	25 (5.0)				
Other heart diseases	497 (3.1)	256 (2.3)	54 (3.4)	95 (5.2)	51 (6.1)	41 (8.2)				
Cerebrovascular diseases	199 (1.3)	82 (0.7)	27 (1.7)	50 (2.7)	24 (2.9)	16 (3.2)				
Disease of the arteries, arterioles and capillaries	122 (0.8)	43 (0.4)	6 (0.4)	26 (1.4)	25 (3.0)	22 (4.4)				
Death, n (%)										
All-causes	1,172 (7.4)	617 (5.5)	152 (9.6)	174 (9.5)	118 (14.2)	111 (22.3)				
Any cardiovascular disease	113 (0.7)	28 (0.3)	16 (1.0)	23 (1.3)	18 (2.2)	28 (5.6)				
Any cancer (including breast cancer)	804 (5.1)	481 (4.3)	108 (6.8)	107 (5.9)	56 (6.7)	52 (10.5)				
Breast cancer	587 (3.7)	374 (3.3)	76 (4.8)	68 (3.7)	37 (4.5)	32 (6.4)				

eTable 2 Number of hospitalizations of cardiovascular disease and deaths by CAC score category during a median follow-up of 4.3 years

Cardiovascular disease was defined by ICD-10 codes I00-199, lymphedema and varicose veins excluded (I88-89 and I83-86 respectively)

Coronary artery disease was defined by ICD-10 codes I20-25, including angina pectoris and myocardial infarction Heart failure was defined by ICD-10 code I50

Other heart diseases was defined by ICD-10 codes I30-49 and I51, including pericarditis, endocarditis, myocarditis, cardiomyopathy and arrhythmia

Cancer was defined by ICD-10 codes C00-99, non-melanoma skin cancer excluded (C44)

Breast cancer was defined by ICD-10 code 50

eTable 3 Number of hospitalizations for other heart diseases (I30-49, I51) during a median follow-up of 4.3 years

ICD-10 code	Diagnosis	N (%)
130	Acute percarditis	- (<1)
131	Other diseases of pericardium	11 (2)
133	Acute and subacute endocarditis	11 (2)
134	Nonrheumatic mitral valve disorders	20 (3)
135	Nonrheumatic aortic valve disorders	54 (9)
138	Endocarditis, valve unspecified	11 (2)
142	Cardiomyopathy	30 (5)
144	Atrioventricular and left bundle-branch block	29 (5)
145	Other conduction disorders	12 (2)
146	Cardiac arrest	16 (3)
147	Paroxysmal tachycardia	42 (7)
148	Atrial fibrillation and flutter	276 (46)
149	Other cardiac arrhythmias	67 (11)
151	Complications and ill-defined descriptions of heart disease	15 (3)

Patients could have more than one hospitalization for other heart disease.

		J 109(0/10 · 1/		
CAC score (Agatston units)	Unadjusted	Model 1	Model 2	Model 3
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Log(CAC+1)	3.9 (3.4-4.4)	2.2 (1.9-2.6)	2.2 (2.0-2.6)	2.2 (1.9-2.5)

eTable 4 Risk of cardiovascular disease by log(CAC+1)

Model 1: adjusted for age at time of CT scan and stratified by calendar year of CT scan

Model 2: adjusted for age at time of CT scan, laterality, treated with anthracyclines and treated with trastuzumab, and stratified by calendar year of CT scan

Model 3: adjusted for age at time of CT scan, laterality, treated with anthracyclines and treated with trastuzumab, and stratified by calendar year of CT scan; model included interaction between log(CAC+1) and anthracyclines

eTable 5 Number of hospitalizations for cardiovascular disease and deaths by CAC score category in patients without and with CVD hospitalization before the radiotherapy planning CT scan

	Patier	nts without	pre-existing	g cardiovas	scular dise	Patie	Patients with pre-existing cardiovascular disease						
			CAC sco	ore (Agatsto	on units)			CAC score (Agatston units)					
	Total (n = 14,501)	0 (n = 10,559)	1-10 (n = 1,447)	11-100 (n = 1,577)	101-400 (n = 651)	>400 (n = 267)	Total (n = 1,414)	0 (n = 620)	1-10 (n = 137)	11-100 (n = 248)	101-400 (n = 179)	>400 (n = 230)	
Hospital admission, n (%)													
Any cardiovascular disease	1,003 (6.9)	522 (4.9)	121 (8.4)	199 (12.6)	98 (15.1)	63 (23.6)	338 (23.9)	121 (19.5)	25 (18.2)	61 (24.5)	56 (31.3)	75 (32.6)	
Coronary artery disease	238 (1.6)	100 (0.9)	33 (2.3)	55 (3.5)	28 (4.3)	22 (8.2)	98 (6.9)	27 (4.4)	<5 (-)	15 (6.0)	23 (12.8)	29 (12.6)	
Heart failure	120 (0.8)	61 (0.6)	12 (0.8)	22 (1.4)	14 (2.2)	11 (4.1)	65 (4.6)	23 (3.7)	<5 (-)	12 (4.8)	13 (7.3)	14 (6.1)	
Other heart diseases	354 (2.4)	192 (1.8)	44 (3.0)	63 (4.0)	37 (5.7)	18 (6.7)	143 (10.1)	64 (10.3)	10 (7.3)	32 (12.9)	14 (7.8)	23 (10.0)	
Death, n (%)													
All-causes	962 (6.6)	555 (5.3)	128 (8.8)	133 (8.4)	87 (13.4)	59 (22.1)	210 (14.9)	62 (10.0)	24 (17.5)	41 (16.5)	31 (17.3)	52 (22.6)	
Any cardiovascular disease	70 (0.5)	20 (0.2)	12 (0.8)	16 (1.0)	13 (2.0)	9 (3.4)	43 (3.0)	8 (1.3)	<5 (-)	7 (2.8)	5 (2.8)	19 (8.3)	
Any cancer (including breast cancer)	695 (4.8)	443 (4.2)	95 (6.6)	85 (5.4)	41 (6.3)	31 (11.6)	109 (7.7)	38 (6.1)	13 (9.5)	22 (8.9)	15 (8.4)	21 (9.1)	
Breast cancer	505 (3.5)	345 (3.3)	65 (4.5)	52 (3.3)	25 (3.8)	18 (6.7)	82 (5.8)	29 (4.7)	11 (8.0)	16 (6.5)	12 (6.7)	14 (6.1)	

Cardiovascular disease was defined by ICD-10 codes 100-199, lymphedema and varicose veins excluded (188-89 and 183-86 respectively)

Coronary artery disease was defined by ICD-10 codes I20-25, including angina pectoris and myocardial infarction

Heart failure was defined by ICD-10 code I50

Other heart diseases was defined by ICD-10 codes I30-49 and I51, including pericarditis, endocarditis, myocarditis, cardiomyopathy and arrhythmia

Cancer was defined by ICD-10 codes C00-99, non-melanoma skin cancer excluded (C44)

Breast cancer was defined by ICD-10 code C50

	Patients without pre-existing cardiovascular disease								
CAC score (Agatston units)	n (%)	Events, n (%)	Incidence rate , per 1000 person- years	HR (95% CI)					
0	10,559 (72.8)	467 (4.4)	9.1	1.0 (ref)					
1-10	1,447 (10.0)	111 (7.7)	15.0	1.2 (0.9-1.5)					
11-100	1,577 (10.9)	193 (12.2)	25.1	1.8 (1.5-2.2)					
101-400	651 (4.5)	93 (14.3)	33.7	1.9 (1.5-2.5)					
>400	267 (1.8)	61 (22.8)	58.8	3.2 (2.4-4.3)					
	Patients	with pre-existin	g cardiovascula	ar disease					
CAC score (Agatston units)	n (%)	Events, n (%)	Incidence rate , per 1000 person- years	HR (95% CI)					
0	620 (43.8)	112 (18.1)	45.6	1.0 (ref)					
1-10	137 (9.7)	27 (19.7)	51.0	0.8 (0.5-1.3)					
11-100	248 (17.5)	60 (24.2)	67.8	1.2 (0.9-1.7)					
101-400	179 (12.7)	55 (30.7)	89.2	1.4 (1.0-2.0)ª					
>400	230 (16.3)	79 (34.3)	103.7	1.5 (1.1-2.0)					

eTable 6 Risk of cardiovascular disease by CAC score category in patients without and with CVD hospitalization before the radiotherapy planning CT scan

CAC = coronary artery calcium; CI = confidence interval; HR = hazard ratio

^a 95% CI lower limit <1.0

Coronary artery disease included all coronary artery disease hospitalizations and death (ICD-10 codes I20-25), including angina pectoris and myocardial infarction

Models were adjusted for age at time of CT scan and stratified by calendar year of CT scan

	Left-sided radiotherapy (n = 8,223)		Right-sided radiotherapy (n = 7,688)		Radiation boost (n = 5,182)		No radiation boost (n = 5,324)		Anthracyclines (n = 4,333)		No anthracyclines (n = 11,582)	
CAC score (Agatston units)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)
0	2.3	1.0 (ref)	2.0	1.0 (ref)	1.8	1.0 (ref)	2.3	1.0 (ref)	1.3	1.0 (ref)	2.5	1.0 (ref)
1-10	5.2	1.9 (1.2-3.1)	3.7	1.4 (0.8-2.6)	4.3	1.9 (0.8-4.8)	4.7	1.6 (0.6-3.9)	3.7	2.4 (0.9-6.6)	4.7	1.6 (1.1-2.4)
11-100	9.7	3.4 (2.3-5.0)	6.7	2.3 (1.4-3.6)	6.8	2.7 (1.2-6.1)	7.8	2.8 (1.4-5.6)	6.4	3.6 (1.5-8.6)	8.5	2.8 (2.0-3.8)
101-400	15.9	5.1 (3.2-8.2)	11.6	3.4 (2.0-5.9)	8.1	2.7 (1.0-7.6) ^a	11.7	4.4 (2.1-9.1)	2.4	1.1 (0.2-8.9)	15.3	4.6 (3.2-6.6)
>400	27.3	8.4 (5.1- 13.9)	26.0	7.4 (4.4- 12.4)	46.8	14.8 (7.0- 31.3)	31.0	10.5 (5.5- 20.3)	20.4	9.1 (2.0- 41.8)	27.0	7.8 (5.4- 11.3)

eTable 7 Risk of coronary artery disease by CAC score category, stratified by treatment

CAC = coronary artery calcium; CI = confidence interval; HR = hazard ratio

^a 95% CI lower limit <1.0

Coronary artery disease included all coronary artery disease hospitalizations and death (ICD-10 codes I20-25), including angina pectoris and myocardial infarction Models in patients who received left-sided or right-sided radiotherapy, and who were treated with and without anthracyclines were adjusted for age at time of CT scan and stratified by calendar year of CT scan

Models in patients who received radiotherapy with and without boost were adjusted for age at time of CT scan, laterality, treated with anthracyclines and treated with trastuzumab, and stratified by calendar year of CT scan; model included interaction between CAC and anthracyclines

Left-sided radiotherapy (n = 8,223)		Right-sided radiotherapy (n = 7,688)		Radiation boost (n = 5,182)		No radiation boost (n = 5,324)		Anthracyclines (n = 4,333)		No anthracyclines (n = 11,582)		
CAC score (Agatston units)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)	Inciden ce rate, per 1000 person- years	HR (95% CI)
0	11.7	1.0 (ref)	10.0	1.0 (ref)	8.8	1.0 (ref)	13.2	1.0 (ref)	14.2	1.0 (ref)	9.7	1.0 (ref)
1-10	17.1	1.2 (1.0- 1.5)ª	18.3	1.5 (1.2-1.9)	11.9	1.3 (0.8- 2.3)	20.0	1.8 (1.2- 2.7)	18.0	1.2 (0.8- 1.8)	17.6	1.4 (1.1- 1.7)
11-100	19.8	1.2 (1.0- 1.5)ª	18.6	1.3 (1.0- 1.6) ^b	15.0	1.5 (0.9- 2.5)	17.3	1.6 (1.1- 2.3)	16.8	1.1 (0.7- 1.6)	19.7	1.3 (1.1- 1.5)
101-400	31.2	1.6 (1.2- 2.0)	30.4	1.9 (1.4-2.5)	21.3	2.3 (1.3- 3.9)	33.1	2.7 (1.9- 4.0)	23.8	1.4 (0.8- 2.5)	31.7	1.8 (1.5- 2.2)
>400	59.5	2.9 (2.2- 3.7)	46.1	2.6 (2.0-3.5)	44.2	3.9 (2.3- 6.8)	52.6	4.1 (2.9- 6.0)	76.7	4.6 (2.4- 8.6)	51.4	2.8 (2.2- 3.4)

eTable 8 Risk of all-cause mortality by CAC score category, stratified by treatment (follow-up until 2018)

CAC = coronary artery calcium; CI = confidence interval; HR = hazard ratio

^a 95% CI lower limit <1.0

^b 95% CI lower limit >1.0

Models were adjusted for age at time of CT scan (natural spline with df=3) and stratified by calendar year of CT scan

Models in patients who received left-sided or right-sided radiotherapy, and who were treated with and without anthracyclines were adjusted for age at time of CT scan and stratified by calendar year of CT scan

Models in patients who received radiotherapy with and without boost were adjusted for age at time of CT scan, laterality, treated with anthracyclines and treated with trastuzumab, and stratified by calendar year of CT scan; model included interaction between CAC and anthracyclines

	Subdistribution HR (95% CI) ^a									
CAC score (Agatston units)	Model 1	Model 2	Model 3							
0	1.0 (ref)	1.0 (ref)	1.0 (ref)							
1-10	1.2 (1.0-1.5) ^b	1.2 (1.0-1.5) ^b	1.2 (1.0-1.5) ^b							
11-100	1.8 (1.5-2.1)	1.8 (1.5-2.1)	1.8 (1.5-2.1)							
101-400	2.2 (1.8-2.7)	2.2 (1.8-2.7)	2.2 (1.8-2.6)							
>400	3.5 (2.9-4.3)	3.5 (2.8-4.3)	3.4 (2.8-4.2)							

eTable 9 Competing risks survival analysis of cardiovascular disease by CAC category

CAC = coronary artery calcium; CI = confidence interval; HR = hazard ratio; ref = reference

^a Competing risk survival analysis as described by Fine and Gray (Fine 1999 J Am Stat Assoc) provides subdistribution hazard ratios.

^b 95% CI lower limit >1.0

Cardiovascular disease included all cardiovascular disease hospitalizations and death (ICD-10 codes 100-199, Lymphedema and varicose veins excluded (I88-89 and I83-86 respectively))

All models were adjusted for age at time of CT scan and stratified by calendar year of CT scan


Model 1: competing risk was all-cause mortality


Model 2: competing risk was cancer hospitalization

Model 3: competing risks were all-cause mortality and cancer hospitalization

eFigure 1 Cumulative incidence curves for CVD by CAC category in the presence of competing risks (Aalen-Johansen estimates and 95% intervals) Cardiovascular disease included all cardiovascular disease hospitalizations and death (ICD-10 codes

Cardiovascular disease included all cardiovascular disease hospitalizations and death (ICD-10 codes 100-199, Lymphedema and varicose veins excluded (I88-89 and I83-86 respectively)). CAC = coronary artery calcium





© 2021 American Medical Association. All rights reserved.